MDD review trains focus on single-use devices
This article was originally published in Clinica
The latest text of the European Commission's draft proposal revising the MDD reinforces the need for manufacturers to justify the claims that their devices are for single-use only (SUDs). Industry has called for a ban on the reprocessing of SUDs within the context of the review. Although such a clause places the onus of the manufacturer to ensure that the single-use claim is thoroughly justified, sources close to be Commission have indicated that the only other alternative would have been to allow SUDs to be reprocessed.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.